187 related articles for article (PubMed ID: 36915469)
1. Tailored chemotherapy for colorectal cancer peritoneal metastases based on a drug-screening platform in patient-derived organoids: a case report.
Prieto I; Barbáchano A; Rodríguez-Salas N; Viñal D; Cortés-Guiral D; Muñoz A; Fernández-Barral A
J Gastrointest Oncol; 2023 Feb; 14(1):442-449. PubMed ID: 36915469
[TBL] [Abstract][Full Text] [Related]
2. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): Rationale and design.
Dumont F; Senellart H; Pein F; Campion L; Glehen O; Goere D; Pocard M; Thibaudeau E
Pleura Peritoneum; 2018 Sep; 3(3):20180120. PubMed ID: 30911664
[TBL] [Abstract][Full Text] [Related]
4. Initial experience of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a French hyperthermic intraperitoneal chemotherapy (HIPEC) expert center.
Ceribelli C; Debs T; Chevallier A; Piche MA; Bereder JM
Surg Endosc; 2020 Jun; 34(6):2803-2806. PubMed ID: 32166545
[TBL] [Abstract][Full Text] [Related]
5. Surgical Options for Peritoneal Surface Metastases from Digestive Malignancies-A Comprehensive Review.
Eftimie MA; Potlog G; Alexandrescu ST
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837456
[TBL] [Abstract][Full Text] [Related]
6. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
7. Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design.
Raoof M; Sullivan KM; Frankel PH; Fakih M; Synold TW; Lim D; Woo Y; Paz IB; Fong Y; Thomas RM; Chang S; Eng M; Tinsley R; Whelan RL; Deperalta D; Reymond MA; Jones J; Merchea A; Dellinger TH
Pleura Peritoneum; 2022 Dec; 7(4):169-177. PubMed ID: 36560966
[TBL] [Abstract][Full Text] [Related]
8. Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
Ripley RT; Davis JL; Kemp CD; Steinberg SM; Toomey MA; Avital I
Trials; 2010 May; 11():62. PubMed ID: 20500867
[TBL] [Abstract][Full Text] [Related]
9. Unresectable peritoneal metastasis treated by pressurized intraperitoneal aerosol chemotherapy (PIPAC) leading to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Alyami M; Mercier F; Siebert M; Bonnot PE; Laplace N; Villeneuve L; Passot G; Glehen O; Bakrin N; Kepenekian V
Eur J Surg Oncol; 2021 Jan; 47(1):128-133. PubMed ID: 31253545
[TBL] [Abstract][Full Text] [Related]
10. Organoids as preclinical models to improve intraperitoneal chemotherapy effectiveness for colorectal cancer patients with peritoneal metastases: Preclinical models to improve HIPEC.
Roy P; Canet-Jourdan C; Annereau M; Zajac O; Gelli M; Broutin S; Mercier L; Paci A; Lemare F; Ducreux M; Elias D; Malka D; Boige V; Goéré D; Jaulin F
Int J Pharm; 2017 Oct; 531(1):143-152. PubMed ID: 28803938
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
12. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study.
van der Kaaij RT; Braam HJ; Boot H; Los M; Cats A; Grootscholten C; Schellens JH; Aalbers AG; Huitema AD; Knibbe CA; Boerma D; Wiezer MJ; van Ramshorst B; van Sandick JW
JMIR Res Protoc; 2017 Jul; 6(7):e136. PubMed ID: 28705789
[TBL] [Abstract][Full Text] [Related]
13. Personalized Identification of Optimal HIPEC Perfusion Protocol in Patient-Derived Tumor Organoid Platform.
Forsythe SD; Sasikumar S; Moaven O; Sivakumar H; Shen P; Levine EA; Soker S; Skardal A; Votanopoulos KI
Ann Surg Oncol; 2020 Dec; 27(13):4950-4960. PubMed ID: 32632882
[TBL] [Abstract][Full Text] [Related]
14. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne.
Casella F; Bencivenga M; Rosati R; Fumagalli UR; Marrelli D; Pacelli F; Macrì A; Donini A; Torroni L; Pavarana M; De Manzoni G
Pleura Peritoneum; 2022 Sep; 7(3):135-141. PubMed ID: 36159218
[TBL] [Abstract][Full Text] [Related]
15. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Girshally R; Demtröder C; Albayrak N; Zieren J; Tempfer C; Reymond MA
World J Surg Oncol; 2016 Sep; 14(1):253. PubMed ID: 27678344
[TBL] [Abstract][Full Text] [Related]
16. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
17. Concomitant intraperitoneal and systemic chemotherapy for extensive peritoneal metastases of colorectal origin: protocol of the multicentre, open-label, phase I, dose-escalation INTERACT trial.
de Boer NL; Brandt-Kerkhof ARM; Madsen EVE; Diepeveen M; van Meerten E; van Eerden RAG; de Man FM; Bouamar R; Koolen SLW; de Hingh IHJT; Bakkers C; Rovers KP; Creemers GM; Deenen MJ; Kranenburg OW; Constantinides A; Mathijssen RHJ; Verhoef C; Burger JWA; ;
BMJ Open; 2019 Dec; 9(12):e034508. PubMed ID: 31818845
[TBL] [Abstract][Full Text] [Related]
18. Peritoneal carcinomatosis arising from rectal or colonic adenocarcinoma treated with cytoreductive surgery (CRS) hyperthermic intraperitoneal chemotherapy (HIPEC): two different diseases.
Tonello M; Ortega-Perez G; Alonso-Casado O; Torres-Mesa P; Guiñez G; Gonzalez-Moreno S
Clin Transl Oncol; 2018 Oct; 20(10):1268-1273. PubMed ID: 29667123
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
20. Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis.
Robella M; Vaira M; De Simone M
World J Surg Oncol; 2016 Apr; 14():128. PubMed ID: 27125996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
